UPDATED Jun 29, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 228.60 | 4.3% | -18.9% | SEK 20.2b | SEK 367.68 | PS80.1x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.10 | -11.3% | 4.8% | US$131.2m | US$9.23 | PB0.7x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.41 | 20.3% | 118.6% | US$1.7b | US$13.83 | PS10.9x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 21.20 | 1.0% | n/a | SEK 20.2b | SEK 34.10 | PS80.1x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
LEGN | US$44.29 | 3.9% | -35.8% | US$8.1b | US$82.50 | PS23.6x | E63.7% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$7.92 | -3.2% | -53.4% | US$205.5m | US$23.22 | PS4.1x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$0.99 | -1.5% | -12.3% | AU$1.1b | AU$1.11 | PS100.9x | E56.7% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$7.79 | -3.7% | 9.3% | US$2.2b | US$25.01 | PS1178.7x | E64.5% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$4.21 | -4.3% | -37.4% | US$270.7m | US$21.20 | PS23.8x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.68 | -0.4% | n/a | HK$59.9b | HK$29.70 | PS9x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$8.22 | 12.4% | -46.5% | US$625.8m | US$14.86 | PS4x | E67.6% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$280.16 | 0.6% | 21.3% | US$6.0b | US$365.07 | PB7x | E63.8% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$40.80 | -0.9% | 851.0% | US$1.5b | US$67.29 | PB10.4x | E65.2% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.5b | n/a | PS2.9x | E98.1% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$2.50 | -12.6% | 28.2% | US$89.6m | US$15.25 | PB9.9x | E66.9% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$8.51 | 4.2% | 27.0% | US$824.6m | US$19.00 | PS82457.9x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.31 | -4.9% | -60.5% | US$196.7m | US$9.25 | PB1.7x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$16.25 | 6.2% | -32.2% | US$2.7b | US$27.35 | PS3.3x | E41.5% | n/a | Pharmaceuticals & Biotech |